DOCSLIB.ORG

Assessment Report on Panax Ginseng C.A. Meyer, Radix Based on Article 16D(1), Article 16F and Article 16H of Directive 2001/83/EC As Amended (Traditional Use)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Assessment Report on Panax Ginseng C.A. Meyer, Radix Based on Article 16D(1), Article 16F and Article 16H of Directive 2001/83/EC As Amended (Traditional Use) 25 March 2014 EMA/HMPC/321232/2012 Committee on Herbal Medicinal Products (HMPC) Assessment report on Panax ginseng C.A. Meyer, radix Based on Article 16d(1), Article 16f and Article 16h of Directive 2001/83/EC as amended (traditional use) Final Herbal substance(s) (binomial scientific name Whole or cut dried root, designated white ginseng; of the plant, including plant part) treated with steam and then dried, designated red ginseng, of Panax ginseng C.A.Meyer Herbal preparation(s) White ginseng: A) Comminuted herbal substance B) Powdered herbal substance C) Dry extract (DER 2-7:1), extraction solvent ethanol 34-40% V/V D) Dry extract (DER 3-7:1), extraction solvent ethanol 40% V/V, containing 4% ginsenosides (sum of Rb1, Rb2, Rc, Rd, Re, Rf, Rg1, Rg2) E) Dry extract (DER 3-7:1), extraction solvent ethanol 57.9% V/V (=50% m/m)-60% V/V F) Dry extract (DER 3.3-5:1), extraction solvent methanol 60% V/V G) Soft extract (DER 1.7-3.2:1), extraction solvent ethanol 60%-70% V/V H) Soft extract (DER 2-6:1), extraction solvent methanol 30% V/V I) Liquid extract (DER 1: 0.8-1.2), extraction solvent ethanol 30.5% V/V (=25% m/m) – 34% V/V J) Liquid extract (DER 1:11-13.6), extraction solvent liquor wine Red ginseng: K) Powdered herbal substance L) Dry extract (DER 2-4.5:1), extraction solvent 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7051 E-mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. ethanol 60% V/V Pharmaceutical forms Comminuted herbal substance (herbal preparation A) as herbal tea for oral use. Herbal preparations F, K, L in solid dosage form for oral use. Herbal preparations G, H, I, J in liquid dosage form for oral use. Herbal preparation B, C, D, E in solid and liquid dosage form. Rapporteur R. Länger Assessor(s) A. Obmann, R. Länger Assessment report on Panax ginseng C.A. Meyer, radix EMA/HMPC/321232/2012 Page 2/124 Table of contents Table of contents ................................................................................................................... 3 1. Introduction ....................................................................................................................... 4 1.1. Description of the herbal substance(s), herbal preparation(s) or combinations thereof .. 4 1.2. Information about products on the market in the Member States ............................... 6 1.3. Search and assessment methodology ..................................................................... 8 2. Data on medicinal use ........................................................................................................ 8 2.1. Information on period of medicinal use in the Community ......................................... 8 2.2. Information on traditional/current indications and specified substances/preparations .. 27 2.3. Specified strength/posology/route of administration/duration of use for relevant preparations and indications ....................................................................................... 29 3. Non-Clinical Data ............................................................................................................. 31 3.1. Overview of available pharmacological data regarding the herbal substance(s), herbal preparation(s) and relevant constituents thereof ........................................................... 31 3.2. Overview of available pharmacokinetic data regarding the herbal substance(s), herbal preparation(s) and relevant constituents thereof ........................................................... 53 3.3. Overview of available toxicological data regarding the herbal substance(s)/herbal preparation(s) and constituents thereof ....................................................................... 55 3.4. Overall conclusions on non-clinical data ................................................................ 59 4. Clinical Data ..................................................................................................................... 60 4.1. Clinical Pharmacology ......................................................................................... 60 4.1.1. Overview of pharmacodynamic data regarding the herbal substance(s)/preparation(s) including data on relevant constituents ........................................................................ 60 4.1.2. Overview of pharmacokinetic data regarding the herbal substance(s)/preparation(s) including data on relevant constituents ........................................................................ 64 4.2. Clinical Efficacy .................................................................................................. 67 4.2.1. Dose response studies...................................................................................... 67 4.2.2. Clinical studies (case studies and clinical trials) ................................................... 67 4.2.3. Clinical studies in special populations (e.g. elderly and children) .......................... 112 4.3. Overall conclusions on clinical pharmacology and efficacy ...................................... 112 5. Clinical Safety/Pharmacovigilance ................................................................................. 112 5.1. Overview of toxicological/safety data from clinical trials in humans ......................... 112 5.2. Patient exposure .............................................................................................. 116 5.3. Adverse events and serious adverse events and deaths ........................................ 116 5.4. Laboratory findings ........................................................................................... 118 5.5. Safety in special populations and situations ......................................................... 118 5.6. Overall conclusions on clinical safety ................................................................... 123 6. Overall conclusions ........................................................................................................ 123 Annex ................................................................................................................................ 124 Assessment report on Panax ginseng C.A. Meyer, radix EMA/HMPC/321232/2012 Page 3/124 1. Introduction 1.1. Description of the herbal substance(s), herbal preparation(s) or combinations thereof • Herbal substance(s) Ginseng radix (European Pharmacopoeia, monograph 01/2008:1523): Ginseng radix consists of the whole or cut dried root, designated white ginseng, treated with steam and then dried, designated red ginseng, of Panax ginseng C.A. Meyer and contains not less than 0.40% for the sum of ginsensosides Rg1 and Rb1 (dried drug). Constituents (Wichtl 2009, Hänsel & Sticher 2010) Ginsenosides: 2-3%, Triterpensaponins: Dammarane and oleanolic acid derivatives More than 200 saponins have been isolated from ginseng species, including roots (processed and native), leaves, stems, flower buds, berries, and seeds. Regarding the chemical structure, ginseng saponins are divided into several groups. The two major groups are protopanaxadiol (PPD)-type saponins with sugar moieties attached to the C3 and/or C20, and the protopanaxatriol (PPT)-group with sugar moieties at C6 and/or C20. (Fig. 1). Other types include the ocotillol-type with a five-membered epoxy-ring at C20, the oleanane –type with a nonsteroidal structure and the dammarane type with a modified C20 side chain. The nomenclature of the ginsenosides (Ra, Rb, Rc, etc.) is related to the TLC- Rf-value, whereby the polarity is decreasing from Ra to Rf, correlating to the grade of glycosylation. So far, from the roots of Panax ginseng about 50 ginsenosides have been identified, mostly belonging to the neutral, bisdesmosidic type (Rb1, Rc, Re, Rg1), but also monodesmosides are present (Rf, Rg2). In general the sugar chains are not branched. Except for Rg3, Rg2, Rh1 and Rs3 all ginsenosides from the unprocessed roots are of 20(S)-PPT or 20(S)-PPD-type. 20(R)-derivatives are characteristic for red ginseng and can be seen as artifacts arising during the treatment with steam. Malonylginsenosides (e.g. mRb1, mRb2) are only present in white ginseng, the malonyl-group is cleaved during the steam processing. (Hänsel & Sticher 2010) Not only red and white ginseng, but also roots and leaves show considerable differences in the ginsenoside spectrum. Especially the small rootlets (“slender tails”) are rich in ginsenosides. Therefore, the qualitative and quantitative composition of and the ratio between certain ginsenosides in ginseng preparations allow conclusions about the processed plant parts and their quality. Assessment report on Panax ginseng C.A. Meyer, radix EMA/HMPC/321232/2012 Page 4/124 R 3 CH3 OH 20 CH3 CH 3 CH3 H3C CH3 R 3 1 6 H3C CH3 R 2 Compound R1 R2 R3 Protopanaxadiol-type 2 1 6 1 Rb1 -O-Glc - Glc H -O-Glc - Glc 2 1 6 1 Rb2 -O-Glc - Glc H -O-Glc - Arabp Rc -O-Glc2-1Glc H -O-Glc6-1Arabf Rd -O-Glc2-1Glc H -O-Glc Compound K (metabolite) -OH H -O-Glc Protopanaxatriol-type Re -OH -O-Glc2-1Rha -O-Glc Rg1 -OH -O-Glc -O-Glc 2 1 Rg2 -OH -O-Glc - Rha -OH Rf -OH -O-Glc2-1Rha -OH Rh1 (metabolite) -OH -O-Glc -OH Fig. 1:Structures of main ginsenosides (Glc: β-D-glucopyranosyl, Arabp: α-L-arabinopyranosyl, Araf: α-L- arabinofuranosyl, Rha: α-L-rhamnopyranosyl) Polysaccharides (Panaxans and Ginsenans): Panaxans (A-U) and ginsenans (PA, PB, S-IA and S-IIA)
Load more

Recommended publications
  • Forest Farming
    Forest Farming Ken Mudge CY ROSE N NA Many sections of the Northeast have been reforested over the past century. Extensive forest cover is seen in this view from Wachu- sett Mountain in central Massachusetts. armers harvest crops from their fields, and agroforestry—a multidisciplinary approach to loggers harvest trees from their forests, agricultural production that achieves diverse, Fbut what do forest farmers harvest? The profitable, sustainable land use by integrating answer is an eclectic collection of non-timber trees with non-timber forest crops. forest crops like maple syrup, medicinal herbs, While some other agroforestry practices begin fruits, gourmet mushrooms, and nuts. with planting young trees that take years to Forest farming is an approach to forest man- mature, forest farming involves planting non- agement that combines some of the manage- timber forest crops beneath the canopy of an ment practices of conventional forestry with established forest. In other words, other agro- those of farming or gardening to achieve forestry practices bring the forest to the crops, an environmentally and economically sus- whereas forest farming brings the crops to the tainable land-use system. It is one of several forest. In this regard it is helpful to consider related practices that fall under the domain of the role of forest farming in overall forest man- Forest Farming 27 agement. A forest farm should be designed to bearing trees including walnuts and peaches, emulate as much as possible a natural forest. but there is no evidence of deliberate culti- This includes characteristics of a healthy forest vation of useful crops beneath the canopy of ecosystem such as species diversity, resilience established forest.
    [Show full text]
  • Clinical Effects of Korean Ginseng, Korean Red Ginseng, Chinese
    2006. Vol. 27. No. 4. 198-208 Korean Journal of Oriental Medicine Original Article Clinical Effects of Korean Ginseng, Korean Red Ginseng, Chinese Ginseng, and American Ginseng on Blood Pressure in Mild Hypertensive Subjects Dong-Jun Choi, Ki-Ho Cho 1) , Woo-Sang Jung 1) , Seong-Uk Park 2) Chang-Ho Han, Won-Chul Lee Department of Oriental Internal Medicine, International Hospital Dong-Guk University Goyang-city, Gyeonggi-do, Korea Department of Cardiovascular and Neurologic Diseases (Stroke Center) College of Oriental Medicine, Kyung-Hee University, Seoul, Korea 1) Stroke & Neurological Disorders Center, East-West Neo Medical Center Kyung-Hee University, Seoul, Korea 2) Background : Ginseng has traditionally been used in oriental countries to recover vital energy from Qi deficiency, and has shown various biomedical effects in the scientific literature. Recent reports suggest that ginseng could regulate blood pressure (BP), but much controversy still remains. Therefore, we intended to assess the anti-hypertensive effect of several ginseng types frequently used in clinics. We also investigated the anti-hypertensive effect on Koreans and Chinese, and by the body type according to Sasang Constitution Medicine (SCM). Methods : The study subjects were recruited from mildly hypertensive patients who exhibited pre-hypertension (120/80 to 139/89 mmHg) and stage I hypertension (140/90 to 159/99 mmHg) in Korea and China. After assigning the subjects into a Korean, a Chinese, a red, and an American ginseng group by randomization, we prescribed ginseng at a dose of 4.5 g per day for 4 weeks. To assess the anti-hypertensive effect, we compared the mean of systolic and diastolic BP between before and after ginseng medication using a 24-hour ambulatory blood pressure monitor (24 hr ABPM).
    [Show full text]
  • Priscila-IAEA
    1 SM/EB-13 E-beam Irradiation of “in nature” Palm: Texture and Color Evaluation Silva, P.V a; Nunes, T.C.F a; Furgeri a, C.; Pitombo b, R.N.M; Hojeije c, K.Y. and Villavicencio, A.L.C.H a a Instituto de Pesquisas Energéticas e Nucleares (IPEN/CNEN-SP), Centro de Tecnologia das Radiações, Laboratório de Detecção de alimentos Irradiados, Cidade Universitária, Av. Professor Lineu Prestes 2242, Butantã CEP 05508-000 São Paulo - SP, Brazil. b Faculdade Ciências Farmacêuticas, Departamento de Tecnologia Farmacêutica e Bioquímica, Universidade de São Paulo, Av. Professor Lineu Prestes 580, Bloco 16 CEP 05508-900 São Paulo – SP, Brazil. c Floresta Indústria e Comércio Ltda. Rodovia Régis Bittencourt BR116, Km 416 Bairro Piúva CEP 118000- 000. Juquiá , São Paulo-SP, Brazil. Email contact of main author: [email protected] [email protected] Abstract The palm tree ( Bactris gasipaes Kunth) is a potential raised species with economic, for the nutritional value of its fruits that can in such way be used in the feeding human being as in the animal, and mainly, for the extraction of the palm that currently has a bigger interest in this culture. Food irradiation is a worldwide technology that aims to improve the product quality, in order to eliminate diverse microorganisms that can spoil the food. Irradiation processing, in the recommended doses, causes very few chemical alterations in foods, nutritional losses are considered insignificant and some of the alterations known found in irradiated foods is not harmful or dangerous. The objective of this work was to evaluate physical characteristics of in nature peach palm, such as color and texture, after combination of e-beam processing and refrigeration.
    [Show full text]
  • Panax Ginseng C.A
    12 March 2013 EMA/HMPC/321232/2012 Committee on Herbal Medicinal Products (HMPC) Assessment report on Panax ginseng C.A. Meyer, radix Based on Article 16d(1), Article 16f and Article 16h of Directive 2001/83/EC as amended (traditional use) Draft Herbal substance(s) (binomial scientific name Whole or cut dried root, designated white ginseng; of the plant, including plant part) treated with steam and then dried, designated red ginseng, of Panax ginseng C.A.Meyer Herbal preparation(s) White ginseng: A) Comminuted herbal substance B) Powdered herbal substance C) Dry extract (DER 2-7:1), extraction solvent ethanol 34-40% V/V D) Dry extract (DERgenuine 3-7:1), extraction solvent ethanol 40% V/V, containing 4% ginsenosides (sum of Rb1, Rb2, Rc, Rd, Re, Rf, Rg1, Rg2) E) Dry extract (DER 3-7:1), extraction solvent ethanol 57.9% V/V (=50% m/m) - 60% V/V F) Dry extract (DER 3.3-5:1), extraction solvent methanol 60% V/V G) Soft extract (DER 1.7-3.2:1), extraction solvent ethanol 60-70% V/V H) Soft extract (DER 2-6:1), extraction solvent methanol 30% V/V I) Liquid extract (DER 1:0.8-1.2), extraction solvent ethanol 30.5% V/V (=25% m/m) – 34% V/V J) Liquid extract (DER 1:11-13.6), extraction solvent liquor wine Red Ginseng: K) Powdered herbal substance L) Dry extract (DER 2-4.5:1), extraction solvent ethanol 60% V/V 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7051 E-mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2013.
    [Show full text]
  • Chemical Authentication of Botanical Ingredients: a Review of Commercial Herbal Products
    MINI REVIEW published: 15 April 2021 doi: 10.3389/fphar.2021.666850 Chemical Authentication of Botanical Ingredients: A Review of Commercial Herbal Products Mihael Cristin Ichim 1* and Anthony Booker 2,3* 1“Stejarul” Research Centre for Biological Sciences, National Institute of Research and Development for Biological Sciences, Piatra Neamt, Romania, 2Research Centre for Optimal Health, School of Life Sciences, College of Liberal Arts and Sciences, University of Westminster, London, United Kingdom, 3Pharmacognosy and Phytotherapy, UCL School of Pharmacy, London, United Kingdom Chemical methods are the most important and widely used traditional plant identification techniques recommended by national and international pharmacopoeias. We have reviewed the successful use of different chemical methods for the botanical authentication of 2,386 commercial herbal products, sold in 37 countries spread over six continents. The majority of the analyzed products were reported to be authentic (73%) but more than a quarter proved to be adulterated (27%). At a national level, the number of products and the adulteration proportions varied very widely. Yet, the adulteration reported for the four countries, from which more than 100 commercial products were purchased Edited by: and their botanical ingredients chemically authenticated, was 37% (United Kingdom), 31% Marcello Locatelli, University of Studies G. d’Annunzio (Italy), 27% (United States), and 21% (China). Simple or hyphenated chemical analytical Chieti and Pescara, Italy techniques have identified the total absence of labeled botanical ingredients, substitution Reviewed by: with closely related or unrelated species, the use of biological filler material, and the hidden Santhosh Kumar J. Urumarudappa, Chulalongkorn University, Thailand presence of regulated, forbidden or allergenic species.
    [Show full text]
  • Acetylcholine Signaling System in Progression of Lung Cancers
    Pharmacology & Therapeutics 194 (2019) 222–254 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Acetylcholine signaling system in progression of lung cancers Jamie R. Friedman a,1, Stephen D. Richbart a,1,JustinC.Merritta,KathleenC.Browna, Nicholas A. Nolan a, Austin T. Akers a, Jamie K. Lau b, Zachary R. Robateau a, Sarah L. Miles a,PiyaliDasguptaa,⁎ a Department of Biomedical Sciences, Joan C. Edwards School of Medicine, 1700 Third Avenue, Huntington, WV 25755 b Biology Department, Center for the Sciences, Box 6931, Radford University, Radford, Virginia 24142 article info abstract Available online 3 October 2018 The neurotransmitter acetylcholine (ACh) acts as an autocrine growth factor for human lung cancer. Several lines of evidence show that lung cancer cells express all of the proteins required for the uptake of choline (choline Keywords: transporter 1, choline transporter-like proteins) synthesis of ACh (choline acetyltransferase, carnitine acetyl- Lung cancer transferase), transport of ACh (vesicular acetylcholine transport, OCTs, OCTNs) and degradation of ACh (acetyl- Acetylcholine cholinesterase, butyrylcholinesterase). The released ACh binds back to nicotinic (nAChRs) and muscarinic Cholinergic receptors on lung cancer cells to accelerate their proliferation, migration and invasion. Out of all components Proliferation of the cholinergic pathway, the nAChR-signaling has been studied the most intensely. The reason for this trend Invasion Anti-cancer drugs is due to genome-wide data studies showing that nicotinic receptor subtypes are involved in lung cancer risk, the relationship between cigarette smoke and lung cancer risk as well as the rising popularity of electronic ciga- rettes considered by many as a “safe” alternative to smoking.
    [Show full text]
  • Panax Ginseng
    Last updated on December 22, 2020 Cognitive Vitality Reports® are reports written by neuroscientists at the Alzheimer’s Drug Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in- development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain health, as well as for age-related health concerns that can affect brain health (e.g., cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports include evaluation of safety data, from clinical trials if available, and from preclinical models. Panax Ginseng Evidence Summary Some studies have shown that ginseng improves cognitive functions and decreases mortality and cancer risk in humans; safe when taken alone, but some drug interactions are known. Neuroprotective Benefit: Numerous studies have reported cognitive benefit with ginseng in healthy people as well as in dementia patients, but the evidence remains inconclusive due to the lack of large, long-term well-designed trials. Aging and related health concerns: Ginseng intake is associated with lower risks for mortality and cancers; also, some benefits seen in Asian people with ischemic heart disease, diabetes, hypertension, hypercholesteremia, and fatigue. Safety: Numerous meta-analyses have reported that ginseng is generally safe when taken alone; however, ginseng interacts with several medications, and high doses may be associated with insomnia, tachyarrhythmias, hypertension, nervousness, and others. 1 Last updated on December 22, 2020 Availability: OTC. In clinical Dose: 200-400 mg/day Chemical formula: e.g., C42H72O14 trials, a standardized ginseng have been tested for (Ginsenoside Rg1); C54H92O23 extract called G115 is often cognitive benefit; higher (Ginsenoside Rb1) used.
    [Show full text]
  • Panax Ginseng) from Different Regions
    molecules Article Analysis of Ginsenoside Content (Panax ginseng) from Different Regions Wei Chen 1,2,3 , Prabhu Balan 2,3 and David G Popovich 1,* 1 School of Food and Advanced Technology, Massey University, Palmerston North 4442, New Zealand; [email protected] 2 Riddet Institute, Massey University, Palmerston North 4442, New Zealand; [email protected] 3 Alpha-Massey Natural Nutraceutical Research Centre, Massey University, Palmerston North 4442, New Zealand * Correspondence: [email protected]; Tel.: +64-63569099 Academic Editor: Vincenzo De Feo Received: 3 September 2019; Accepted: 25 September 2019; Published: 26 September 2019 Abstract: Recently Panax ginseng has been grown as a secondary crop under a pine tree canopy in New Zealand (NZ). The aim of the study is to compare the average content of ginsenosides from NZ-grown ginseng and its original native locations (China and Korea) grown ginseng. Ten batches of NZ-grown ginseng were extracted using 70% methanol and analyzed using LC-MS/MS. The average content of ginsenosides from China and Korea grown ginseng were obtained by collecting data from 30 and 17 publications featuring China and Korea grown ginseng, respectively. The average content of total ginsenosides in NZ-grown ginseng was 40.06 3.21 mg/g (n = 14), which showed significantly ± (p < 0.05) higher concentration than that of China grown ginseng (16.48 1.24 mg/g, n = 113) and ± Korea grown ginseng (21.05 1.57 mg/g, n = 106). For the individual ginsenosides, except for the ± ginsenosides Rb2, Rc, and Rd, ginsenosides Rb1, Re, Rf, and Rg1 from NZ-grown ginseng were 2.22, 2.91, 1.65, and 1.27 times higher than that of ginseng grown in China, respectively.
    [Show full text]
  • Effect of Ganoderma Lucidum (Reishi) on Hematological Parameters
    Available online at www.ijmrhs.com cal R edi ese M ar of c l h a & n r H u e o a J l l t h International Journal of Medical Research & a S n ISSN No: 2319-5886 o c i t i Health Sciences, 2018, 7(3): 151-157 e a n n c r e e t s n I • • IJ M R H S Effect of Ganoderma lucidum (Reishi) on Hematological Parameters in Wistar Rats Hammad Ahmed and Muhammad Aslam* Department of Pharmacology, Faculty of Pharmacy, Ziauddin University, Karachi, Pakistan *Corresponding e-mail: [email protected] ABSTRACT Ganoderma lucidum (Reishi), has been used in Traditional Chinese Medicine (TCM) for 5000 years or more. In China and Japan Ganoderma lucidum has been used in folk medicine, commonly in the treatment of neurasthenia, insomnia, hepatopathy, nephritis, gastric ulcers, asthma, and hypertension. In this study we have evaluated the effect of Ganoderma lucidum on hematological parameters in Wistar rats. The extract was given orally by gavage at the dose of 150 mg/kg and 300 mg/kg body weight. The result of our study shows extremely significant increase in the hemoglobin level, platelet count and leukocyte count more specifically at a dose of 150 mg/kg of Ganoderma lucidum extract when compare with normal control group. However, at a dose of 300 mg/kg of GLE, significant increase in hemoglobin level and extremely significant increase in leukocyte count were observed. Whereas, insignificant result was observed at both the doses of GLE in case of hematocrit level, MCV, MCHC, MCH and RBC count.
    [Show full text]
  • Araliaceae – Ginseng Family
    ARALIACEAE – GINSENG FAMILY Plant: some herbs (perennial), woody vines, shrubs and trees Stem: usually pithy Root: sometimes with rhizomes Leaves: simple or palmately compound but rarely 2’s or 3’s, often thickened and large, mostly alternate (rarely opposite or whorled); usually with stipules that forms a stem sheath; often with star-shaped hairs Flowers: mostly perfect or unisexual (monoecious or dioecious), regular (actinomorphic); flowers very small, mostly in umbels; sepals 5, often forming small teeth or none, mostly 5(-10) petals; mostly 5(-10) stamens; ovary inferior, 2-5 (10) fused carpels Fruit: berry or drupe, oily Other: mostly tropical and subtropical, a few oranamentals; similar to Apiaceae; Dicotyledons Group Genera: 70+ genera; locally Aralia (spikenard), Hedera (English Ivy), Oplopanax, Panax (ginseng) WARNING – family descriptions are only a layman’s guide and should not be used as definitive Araliaceae (Ginseng Family) – 5 (mostly) sepals and petals (often 5-lobed), often in umbels or compound umbels; leaves simple or more often compound; fruit a berry or drupe Examples of common genera Devil's Walkingstick [Hercules’ Club] Wild Sarsaparilla Aralia spinosa L. Aralia nudicaulis L. Devil's Club [Devil’s Walking Stick; Alaskan Ginseng] Oplopanax horridus (Sm.) Miq. English Ivy Hedera helix L. (Introduced) Dwarf Ginseng Panax trifolius L. ARALIACEAE – GINSENG FAMILY Wild Sarsaparilla; Aralia nudicaulis L. Devil's Walkingstick [Hercules’ Club]; Aralia spinosa L. English Ivy; Hedera helix L. (Introduced) Devil's Club [Devil’s
    [Show full text]
  • Imaging Functional Brain Connectivity
    Imaging Functional Brain Connectivity: pharmacological modulation, aging & Alzheimer’s disease Bernadet L. Klaassens 1 Table of contents Chapter 1 3 Introduction and aims Part I: Pharmacological challenge effects on brain connectivity in healthy young adults Chapter 2 10 Single-dose serotonergic stimulation shows widespread effects on functional brain connectivity (NeuroImage 2015 Nov; 122: 440-450) Chapter 3 31 Time related effects on functional brain connectivity after serotonergic and cholinergic neuromodulation (Human Brain Mapping 2017 Jan; 38 (1): 308-325) Part II: Functional brain connectivity and neuromodulation in older age and Alzheimer’s disease Chapter 4 60 Diminished posterior precuneus connectivity with the default mode network differentiates normal aging from Alzheimer’s disease (Frontiers in Aging Neuroscience 2017 Apr; 9: 1-13) Chapter 5 84 Serotonergic and cholinergic modulation of functional brain connectivity: a comparison between young and older adults ( NeuroImage 2018 Apr; 169: 312-322) Chapter 6 108 Imaging cholinergic and serotonergic neurotransmitter networks in Alzheimer’s disease in vivo (Submission at Alzheimer’s and Dementia) Chapter 7 131 Summary and general discussion 2 Chapter 1 Introduction and aims Brain function relies heavily on neural communication and connections. Better understanding of the mechanisms that are related to maintenance or deterioration of brain function requires a technique that takes into account the elaborate nature of the central nervous system (CNS). A useful method for that purpose is to assess the brain’s functional connectivity. Brain regions are functionally connected to each other when they exhibit correlating activation patterns (Friston et al., 1993), illustrating the complex organization of neural networks. Interactions between regions and within networks largely depend on chemical transmission between neurons.
    [Show full text]
  • Oxidative Stress and Parkinson's Disease: New Hopes in Treatment with Herbal Antioxidants
    See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/283728452 Oxidative stress and Parkinson's disease: New hopes in treatment with herbal antioxidants Article in Current pharmaceutical design · November 2015 CITATIONS READS 43 1,053 4 authors, including: Mahmoud Bahmani Hedayatollah Shirzad 219 PUBLICATIONS 2,021 CITATIONS Shahrekord University of Medical Sciences 106 PUBLICATIONS 1,357 CITATIONS SEE PROFILE SEE PROFILE Mahmoud Rafieian-kopaei Shahrekord University of Medical Sciences 337 PUBLICATIONS 5,110 CITATIONS SEE PROFILE Some of the authors of this publication are also working on these related projects: Genetic mapping of deafness in Iran View project expression of anti-oxidative stress genes in ulcerative colitis View project All content following this page was uploaded by Mahmoud Bahmani on 28 November 2015. provided by shahrekord university of medical scinces The user has requested enhancement of the downloaded file. View metadata, citation and similar papers at core.ac.uk CORE brought to you by Send Orders for Reprints to [email protected] Current Pharmaceutical Design, 2016, 22, 000-000 1 Oxidative Stress and Parkinson’s Disease: New Hopes in Treatment with Herbal Antioxidants Amir Sarrafchi1, Mahmoud Bahmani2, Hedayatollah Shirzad1 and Mahmoud Rafieian-Kopaei1* 1Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran; 2Food and Bev- erages Safety Research Center, Urmia University of Medical Sciences, Urmia, Iran Abstract: Parkinson's disease (PD) is a neurodegenerative disorder due to dopamine deficit in substatia nigra. PD is mainly a sporadic disease with unestablished etiology. However, exposure to environmental toxins, head trauma, Please provide corresponding author(s) inflammation, and free radicals are potential reasons.
    [Show full text]